{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:01:54Z","timestamp":1789693314355,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Multiple Sclerosis Society and the Damial Foundation","id":[{"id":"https:\/\/ror.org\/03019wv17","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mesenchymal stem cell-neural progenitors (MSC-NP) are a bone marrow mesenchymal stem cell\u2013derived population of cells with trophic and immunomodulatory properties with therapeutic potential in multiple sclerosis (MS). Early phase clinical trials have investigated the safety and efficacy of intrathecal administration of autologous MSC-NPs in people with progressive MS. To better understand the biological response to MSC-NP treatment, we analyzed cerebrospinal fluid (CSF) biomarkers in 2 separate cohorts of trial subjects with secondary progressive or primary progressive MS from both a phase 2 trial (n\u2009=\u200950) and an expanded access trial (n\u2009=\u200943) who received repeated administrations of autologous MSC-NPs. Candidate biomarkers identified through proteomic screening were validated in both cohorts, revealing a panel of 4 biomarkers (CCL2, C-C motif chemokine ligand-2; MMP9, matrix metalloproteinase-9; SCF, stem cell factor\/c-kit ligand; and CHIT1, chitotriosidase-1) that were significantly changed in CSF but not serum following treatment. Other MS biomarkers neurofilament light and glial fibrillary acidic protein were unchanged following treatment but correlated with age, and both age and Expanded Disability Status Scale (EDSS), respectively. The specific biomarker changes observed following MSC-NP injections suggest distinct biological effects following MSC-NP treatment. These biomarkers help define the pharmacodynamic response to MSC-NP treatment as well as guide the design of future clinical studies.<\/jats:p>","DOI":"10.1093\/stcltm\/szag083","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:10:00Z","timestamp":1788520200000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of intrathecal injection of mesenchymal stem cell-neural progenitors on cerebrospinal fluid biomarkers in progressive multiple sclerosis"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-3059","authenticated-orcid":false,"given":"Violaine K","family":"Harris","sequence":"first","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jiang","sequence":"additional","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ricciarini","sequence":"additional","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Jagid","sequence":"additional","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"McCormick","sequence":"additional","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Kizilbash","sequence":"additional","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5043-5649","authenticated-orcid":false,"given":"Saud A","family":"Sadiq","sequence":"additional","affiliation":[{"name":"Tisch Multiple Sclerosis Research Center of New York , New York, NY 10019,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091720021478900_szag083-B1","doi-asserted-by":"crossref","first-page":"1517369","DOI":"10.3389\/fcell.2025.1517369","article-title":"Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges","volume":"13","author":"Sheikhi","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"2026091720021478900_szag083-B2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5966\/sctm.2012-0015","article-title":"Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis","volume":"1","author":"Harris","year":"2012","journal-title":"Stem Cells Transl Med"},{"key":"2026091720021478900_szag083-B3","doi-asserted-by":"crossref","first-page":"e0290069","DOI":"10.1371\/journal.pone.0290069","article-title":"Mesenchymal stem cell-neural progenitors are enriched in cell signaling molecules implicated in their therapeutic effect in multiple sclerosis","volume":"18","author":"Harris","year":"2023","journal-title":"PLoS One"},{"key":"2026091720021478900_szag083-B4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2011.08.036","article-title":"Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis","volume":"313","author":"Harris","year":"2012","journal-title":"J Neurol Sci"},{"key":"2026091720021478900_szag083-B5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1186\/s13287-021-02563-8","article-title":"Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis","volume":"12","author":"Brown","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2026091720021478900_szag083-B6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"key":"2026091720021478900_szag083-B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13287-024-03765-6","article-title":"Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial","volume":"15","author":"Harris","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"2026091720021478900_szag083-B8","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000928","article-title":"Mesenchymal stem cell-derived neural progenitors in progressive MS: two-year follow-up of a phase I study","volume":"8","author":"Harris","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026091720021478900_szag083-B9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/stcltm\/szab017","article-title":"Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis","volume":"11","author":"Petrou","year":"2022","journal-title":"Stem Cells Transl Med"},{"key":"2026091720021478900_szag083-B10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1474-4422(25)00249-2","article-title":"Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications","volume":"24","author":"Chitnis","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026091720021478900_szag083-B11","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026091720021478900_szag083-B12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1044-5323(02)00125-2","article-title":"The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)","volume":"15","author":"Mahad","year":"2003","journal-title":"Semin Immunol"},{"key":"2026091720021478900_szag083-B13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.27472","article-title":"A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis","volume":"65","author":"Cudkowicz","year":"2022","journal-title":"Muscle Nerve"},{"key":"2026091720021478900_szag083-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ana.25302","article-title":"Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis","volume":"84","author":"Oh","year":"2018","journal-title":"Ann Neurol"},{"key":"2026091720021478900_szag083-B15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/rme-2023-0005","article-title":"Mesenchymal stem cell-derived neural progenitors attenuate proinflammatory microglial activation via paracrine mechanisms","volume":"18","author":"Harris","year":"2023","journal-title":"Regen Med"},{"key":"2026091720021478900_szag083-B16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3389\/fimmu.2017.00531","article-title":"Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients","volume":"8","author":"Khaibullin","year":"2017","journal-title":"Front Immunol"},{"key":"2026091720021478900_szag083-B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s004010051003","article-title":"Expression of stem cell factor and c-kit receptor in neural cells after brain injury","volume":"97","author":"Zhang","year":"1999","journal-title":"Acta Neuropathol"},{"key":"2026091720021478900_szag083-B18","doi-asserted-by":"crossref","first-page":"e00837","DOI":"10.1016\/j.heliyon.2018.e00837","article-title":"Stem cell factor induces polarization of microglia to the neuroprotective phenotype in vitro","volume":"4","author":"Terashima","year":"2018","journal-title":"Heliyon"},{"key":"2026091720021478900_szag083-B19","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001148","article-title":"Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026091720021478900_szag083-B20","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1038\/s41467-024-49312-y","article-title":"CHIT1 at diagnosis predicts faster disability progression and reflects early microglial activation in multiple sclerosis","volume":"15","author":"Beli\u00ebn","year":"2024","journal-title":"Nat Commun"},{"key":"2026091720021478900_szag083-B21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.matbio.2017.11.007","article-title":"The gelatinases, MMP-2 and MMP-9, as fine tuners of neuroinflammatory processes","volume":"75-76","author":"Hannocks","year":"2019","journal-title":"Matrix Biol"},{"key":"2026091720021478900_szag083-B22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/1352458512466929","article-title":"CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis","volume":"19","author":"Romme Christensen","year":"2013","journal-title":"Mult Scler"},{"key":"2026091720021478900_szag083-B23","doi-asserted-by":"crossref","first-page":"11127","DOI":"10.1523\/JNEUROSCI.23-35-11127.2003","article-title":"Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan","volume":"23","author":"Larsen","year":"2003","journal-title":"J Neurosci"},{"key":"2026091720021478900_szag083-B24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pneurobio.2013.03.004","article-title":"Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system","volume":"105","author":"Verslegers","year":"2013","journal-title":"Prog Neurobiol"},{"key":"2026091720021478900_szag083-B25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-018-08140-7","article-title":"Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation","volume":"10","author":"Starossom","year":"2019","journal-title":"Nat Commun"},{"key":"2026091720021478900_szag083-B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41591-022-02097-3","article-title":"Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study","volume":"29","author":"Genchi","year":"2023","journal-title":"Nat Med"},{"key":"2026091720021478900_szag083-B27","doi-asserted-by":"crossref","first-page":"578613","DOI":"10.1016\/j.jneuroim.2025.578613","article-title":"Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01)","volume":"403","author":"Petrou","year":"2025","journal-title":"J Neuroimmunol"},{"key":"2026091720021478900_szag083-B28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jcyt.2016.08.007","article-title":"Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis","volume":"18","author":"Harris","year":"2016","journal-title":"Cytotherapy"},{"key":"2026091720021478900_szag083-B29","doi-asserted-by":"crossref","first-page":"1756286419892360","DOI":"10.1177\/1756286419892360","article-title":"Safety of long-term intrathecal methotrexate in progressive forms of MS","volume":"12","author":"Stark","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2026091720021478900_szag083-B30","doi-asserted-by":"crossref","first-page":"e214915","DOI":"10.1212\/WNL.0000000000214915","article-title":"Intrathecal mesenchymal stem cells in progressive multiple sclerosis: a randomized, double-blind, placebo-controlled trial (SMART-MS)","volume":"106","author":"Kvistad","year":"2026","journal-title":"Neurology"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/10\/szag083\/71190919\/szag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/10\/szag083\/71190919\/szag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:02:25Z","timestamp":1789689745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag083\/8812656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag083","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,18]]},"article-number":"szag083"}}